Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Results for EoE Treatment EP-104GI
- Eupraxia Pharmaceuticals reports promising Phase 1b/2a trial results for EP-104GI, showing improved outcomes in eosinophilic esophagitis patients.
- The RESOLVE trial indicates EP-104GI may surpass current treatment standards, enhancing symptom relief and reducing inflammation.
- Eupraxia plans to share more detailed trial findings in a webinar on May 9, 2025, highlighting ongoing commitment to EoE treatment.
Eupraxia Pharmaceuticals Unveils Promising Phase 1b/2a Trial Results for EP-104GI in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology firm located in Victoria, British Columbia, announces significant advancements in its RESOLVE Phase 1b/2a clinical trial for EP-104GI, a potential treatment for eosinophilic esophagitis (EoE). Recently disclosed nine-month data reveals that all three patients who received a 48 mg dose of EP-104GI demonstrate either sustained or improved treatment outcomes. This marks a crucial milestone for Eupraxia, as it is the first time the company shares such long-term efficacy results for this investigational therapy.
EoE is a chronic condition characterized by inflammation of the esophagus, affecting over 450,000 individuals in the United States alone. Dr. Evan S. Dellon, the Chairman of Eupraxia's Gastrointestinal Clinical Advisory Board, underscores the urgent need for innovative therapies to address this condition, which often leads to significant health complications if left untreated. The company’s findings from the RESOLVE trial suggest that EP-104GI could potentially exceed the current treatment standards available to patients, improving symptom relief and overall tissue health while also reducing eosinophil counts—an indicator of inflammation in the esophagus.
The RESOLVE trial involves varied dosing cohorts, with Cohort 5 receiving a total of 48 mg via 12 injections and Cohort 6 receiving a higher dose of 64 mg through 16 injections, aimed at a broader area of the esophagus. CEO Dr. James Helliwell expresses optimism regarding these preliminary results, indicating that they reflect a significant step forward in the development of therapies for EoE. The company plans to discuss these findings in greater detail during an upcoming webinar on May 9, 2025, where further data from the trial is also anticipated.
In addition to the positive trial results, Eupraxia Pharmaceuticals continues to address the growing prevalence of EoE, which has been rapidly increasing in recent years. The company's dedication to developing effective treatments for this condition positions it as a key player in the biotechnology sector, particularly in the gastrointestinal therapeutic area.
As Eupraxia prepares to share additional insights and data from the RESOLVE trial, the biotechnology community watches closely. The successful development of EP-104GI could not only improve the quality of life for countless EoE patients but also solidify Eupraxia's reputation as an innovator in the field of gastrointestinal diseases.